HTFL — Heartflow, Inc. Common Stock stock price, charts and financials
QT51Heartflow, Inc. Common StockHeartflow, Inc. Common Stock (NASDAQ: HTFL) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.88 | Insider Own | 30.53% | Shs Outstand | 86.24M | Perf Week | 14.23% |
| Market Cap | 2.49B | Forward P/E | - | EPS next Y | -0.27 | Insider Trans | -9.10% | Shs Float | 66.29M | Perf Month | 3.97% |
| Enterprise Value | 2.49B | PEG | - | EPS next Q | -0.14 | Inst Own | - | Short Float | 8.86% | Perf Quarter | -3.87% |
| Income | -26.10M | P/S | 12.98 | EPS this Y | 44.76% | Inst Trans | - | Short Ratio | 3.93 | Perf Half Y | 10.89% |
| Sales | 191.42M | P/B | 37.17 | EPS next Y | 43.68% | ROA | -32.51% | Short Interest | 5.87M | Perf YTD | -1.13% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | 830.46% | 52W High | 42.76 -30.08% | Perf Year | - |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -21.94% | 52W Low | 20.88 43.17% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 78.06% | Volatility | 4.34% 5.62% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 13.02 | EPS Y/Y TTM | 42.48% | Oper. Margin | -35.83% | ATR (14) | 1.58 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.57 | Sales Y/Y TTM | 51.59% | Profit Margin | -58.42% | RSI (14) | 58.03 | Recom | 2.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.57 | EPS Q/Q | -33.33% | SMA20 | 11.49% | Beta | 1.74 | Target Price | 37.00 |
| Payout | 0.00% | Debt/Eq | 0.09 | Sales Q/Q | 43.24% | SMA50 | 0.10% | Rel Volume | 0.51 | Prev Close | 28.82 |
| Employees | 843 | LT Debt/Eq | 0.05 | Earnings | Sep 18 | SMA200 | -0.64% | Avg Volume | 1.46M | Price | 29.89 |
| IPO Date | Aug 07, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 14.73% 5.80% | Net Debt/EBITDA | -0.07 | Volume | 746,207 | Change | 3.73% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-31-26 | Initiated | Baird | Outperform | $34 |
| Jul-15-26 | Reiterated | Stifel Nicolaus | $35 → $40 | |
| May-15-26 | Reiterated | Canaccord Genuity | Buy | $35 → $37 |
| May-15-26 | Reiterated | Wells Fargo | Overweight | $38 → $37 |
| Jan-28-26 | Initiated | Wells Fargo | Overweight | $38 |
| Sep-02-25 | Initiated | Morgan Stanley | Equal Weight | $35 |
| Sep-02-25 | Initiated | Canaccord | Buy | $35 |
| Sep-02-25 | Initiated | Stifel | Buy | $35 |
| Sep-02-25 | Initiated | Piper Sandler | Overweight | $38 |
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | |
|---|---|---|---|---|---|
| Total Revenue | 191 | 176 | 126 | — | |
| Cost of Goods Sold Incl. D&A | 42 | 41 | 31 | — | |
| Gross Profit | 149 | 135 | 94 | — | |
| Selling, General and Administrative Excl. Other | 145 | 134 | 112 | — | |
| Research and Development | 73 | 65 | 44 | — | |
| Other Operating Expense | 0 | 0 | 0 | — | |
| Operating Income | -69 | -64 | -61 | — | |
| Interest Expense | 10 | 15 | 23 | — | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | -33 | -38 | -12 | — | |
| Net Income Before Taxes | -112 | -117 | -96 | — | |
| Income Taxes | 0 | 0 | 0 | — | |
| Consolidated Net Income | -111 | -117 | -96 | — | |
| Net Income From Continuing Operations | -111 | -117 | -96 | — | |
| Net Income | -111 | -117 | -96 | — | |
| EPS (Recurring) | -0.88 | -0.32 | -1.53 | — | |
| EPS (Basic, Before Extraordinaries) | -0.88 | -0.32 | -1.53 | — | |
| EPS (Diluted) | -0.88 | -0.32 | -1.53 | — | |
| EBITDA | -92 | -93 | -65 | — | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | 57.76 | 61.12 | — | — | |
| Gross Margin | 78.01 | 76.70 | 74.60 | — | |
| Operating Margin | -36.13 | -36.36 | -48.41 | — | |
| Net Margin | -58.12 | -66.48 | -76.19 | — | |
| Shares Outstanding | 369 | 369 | 63 | — | |
| Market Capitalization | 11,031 | 10,756 | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Farquhar John C.M. | Chief Executive Officer | Jul 30 '26 | Option Exercise | 5.06 | 31,220 | 158,013 | 466,593 | Jul 31 |
| Verghese Vikram | Chief Financial Officer | Jul 27 '26 | Option Exercise | 2.22 | 22,522 | 49,999 | 255,898 | Jul 28 |
| Lightcap Jeffrey C | Director | Jul 24 '26 | Option Exercise | 19.00 | 47,420 | 900,980 | 293,681 | Jul 28 |
| BARABE TIMOTHY C | Director | Jul 22 '26 | Option Exercise | 19.00 | 3,710 | 70,490 | 188,231 | Jul 24 |
| Verghese Vikram | Chief Financial Officer | Jul 21 '26 | Option Exercise | 2.22 | 22,522 | 49,999 | 233,376 | Jul 23 |
| BARABE TIMOTHY C | Director | Jul 17 '26 | Option Exercise | 19.00 | 5,000 | 95,000 | 184,521 | Jul 20 |
| Rogers Campbell | Chief Medical Officer | Jul 15 '26 | Option Exercise | 19.00 | 9,219 | 175,161 | 97,950 | Jul 17 |
| Rogers Campbell | Chief Medical Officer | Jul 15 '26 | Sale | 25.72 | 9,219 | 237,113 | 88,731 | Jul 17 |
| Farquhar John C.M. | Chief Executive Officer | Jul 10 '26 | Sale | 27.75 | 22,562 | 626,096 | 435,373 | Jul 13 |
| WELDON WILLIAM C | Director | Jul 08 '26 | Option Exercise | 8.33 | 51,369 | 427,905 | 243,931 | Jul 10 |
| Farquhar John C.M. | Chief Executive Officer | Jun 24 '26 | Sale | 35.00 | 38,900 | 1,361,500 | 457,935 | Jun 26 |
| Rogers Campbell | Chief Medical Officer | Jun 15 '26 | Option Exercise | 2.22 | 10,000 | 22,200 | 88,731 | Jun 17 |
| Farquhar John C.M. | Chief Executive Officer | Jun 10 '26 | Sale | 28.50 | 22,562 | 643,017 | 496,835 | Jun 12 |
| Rogers Campbell | Chief Medical Officer | May 18 '26 | Option Exercise | 19.00 | 9,219 | 175,161 | 87,950 | May 20 |
| Rogers Campbell | Chief Medical Officer | May 18 '26 | Sale | 28.34 | 9,219 | 261,266 | 78,731 | May 20 |